Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

SIMPLE SUMMARY: Considering the favorable overall safety profile of trastuzumab emtansine (T-DM1), the low expected rate of cardiotoxicity, and the synergistic effect of anthracyclines with Human Epidermal Growth Factor Receptor 2 (HER2)-targeting agents, it is hypothesized that T-DM1 may be safely...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: López-Miranda, Elena, Pérez-García, José Manuel, Di Cosimo, Serena, Brain, Etienne, Ravnik, Maja, Escrivá-de-Romaní, Santiago, Vidal, Maria, Gligorov, Joseph, Borštnar, Simona, Calabuig, Laura, Sampayo-Cordero, Miguel, Malfettone, Andrea, Llombart-Cussac, Antonio, Suter, Thomas M., Cortés, Javier
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7760511/
https://ncbi.nlm.nih.gov/pubmed/33255658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123509
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires